CAS 2097132-93-7

Formule : C27H32FN9O2

InChI : InChI=1S/C27H32FN9O2/c1-16-11-22(33-23-12-17(2)35-36-23)34-25(31-16)19-7-9-27(39-4,10-8-19)26(38)32-18(3)20-5-6-24(29-13-20)37-15-21(28)14-30-37/h5-6,11-15,18-19H,7-10H2,1-4H3,(H,32,38)(H2,31,33,34,35,36)/t18-,19?,27?/m0/s1

Code InChI : GBLBJPZSROAGMF-SIYOEGHHSA-N

SMILES : CC1=CC(=NN1)NC2=NC(=NC(=C2)C)C3CCC(CC3)(C(=O)N[C@@H](C)C4=CN=C(C=C4)N5C=C(C=N5)F)OC

(1r,4r)-N-[(1S)-1-[6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl]ethyl]-1-methoxy-4-{4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}cyclohexane-1-carboxamide

CAS : 2097132-93-7

(1r,4r)-N-[(1S)-1-[6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl]ethyl]-1-methoxy-4-{4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}cyclohexane-1-carboxamide

Formule : C₂₇H₃₂FN₉O₂

Degré de pureté : ≥95%

Masse moléculaire : 533.6

Ref: 54-PC1030638

trans-Pralsetinib

CAS : 2097132-93-7

trans-Pralsetinib (trans-BLU-667) is a RET inhibitor. It targets RET kinase to suppress tumor growth driven by RET mutations or rearrangements; used in lung and thyroid cancer research.

Formule : C₂₇H₃₂FN₉O₂

Degré de pureté : 98.06%

Couleur et forme : Transparent Viscous

Masse moléculaire : 533.6

Ref: TM-T10823

(1r,4r)-N-[(1S)-1-[6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl]ethyl]-1-methoxy-4-{4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}cyclohexane-1-carboxamide

CAS : 2097132-93-7

Degré de pureté : 96.07%

Ref: IN-DA01V4W5